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ABSTRACT
Objective:  Daily inhaled corticosteroid (ICS) and long-acting beta-2-agonist (LABA) combinations 
comprising either regular maintenance therapy with ICS/LABA plus as-needed short-acting beta-2-
agonist (SABA) or ICS-formoterol combinations used as maintenance and reliever therapy (MART) 
are recommended for moderate asthma. This analysis compares the direct costs of twice-daily 
fluticasone propionate/salmeterol (FP/salm) and budesonide/formoterol MART in three Southeast 
Asian countries.
Methods: A literature review identified three randomized trials in patients with asthma (≥ 12 years) 
comparing regular twice-daily FP/salm with as-needed SABA versus MART in moderate asthma: 
AHEAD (NCT00242775/17 countries/2309 patients), COMPASS (AstraZeneca study SD-039-0735/16 
countries/3335 patients), and COSMOS (AstraZeneca study SD-039-0691/16 countries/2143 patients). 
Economic analyses, conducted from a healthcare sector perspective (medication costs + healthcare 
utilization costs), applied unit costs from countries where healthcare costs are publicly available: 
Indonesia, Thailand and Vietnam. Results are expressed in British pound sterling (GBP/patient/year).
Results:  Annual exacerbation rates were low and differences between treatment strategies were 
small (range, FP/salm: 0.31–0.38, MART: 0.24–0.25) although statistically significant in favor of MART. 
Total average (minimum-maximum) direct costs (in GBP/patient/year) across the three studies were 
£187 (£137–£284), £158 (£125–£190), and £151 (£141–£164) for those who used FP/salm, and 
£242 (£217–£267), £284 (£237–£340) and £266 (£224–£315) for MART in Indonesia, Thailand and 
Vietnam, respectively. On average, total direct costs/patient/year with FP/salm were 22.8%, 44.6% 
and 43.0% lower than with MART for Indonesia, Thailand and Vietnam, respectively.
Conclusions:  In the three countries evaluated, total treatment costs with regular twice-daily FP/salm 
were consistently lower than with budesonide/formoterol MART due to lower direct healthcare costs.
Introduction
The severity of a patient’s asthma is based on the level of 
treatment required to control symptoms and to minimize the 
risk of exacerbations and, in this context, moderate asthma 
is defined as asthma that is well controlled with low dose 
daily inhaled corticosteroid (ICS) and long-acting beta-2-ag-
onist (LABA) combinations comprising either regular main-
tenance therapy with ICS/LABA plus as-needed short-acting 
beta-2-agonist (SABA) as reliever therapy or ICS-formoterol 
combinations used as both maintenance and reliever therapy 
(MART) (1). Approximately 10–30% of patients with asthma 
are reported to experience exacerbations (2–4). Although poor 
asthma control and risk of exacerbation are related, they are 
not exactly concordant (5) and it is therefore important to 
assess both separately when considering treatment options.
In clinical practice, choice of treatment is based on evi-
dence of efficacy and safety, cost, and individual patient 
factors (1). The efficacy and safety of regular maintenance 
therapy with the ICS/LABA combination fluticasone propi-
onate/salmeterol (FP/salm) has been well-established in 
patients with moderate to severe asthma (6–15). MART 
treatment regimen with the combination of budesonide and 
formoterol has well-described efficacy in reducing the risk 
of severe exacerbations in studies of patients with moderate 
to severe asthma and a history of exacerbations (16,17).
In Southeast Asia, chronic respiratory disease is a leading 
cause of morbidity and mortality, imposing a huge economic 
burden (18). The cost of healthcare, including access to 
cost-effective medications, is an important aspect of tackling 
this burden (18). Previous studies comparing the costs of 
the FP/salm and MART regimens have mainly focused on 
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Table 1. study design of the three clinical studies.
AHEADa COMPASSb COSMOSc
Study design 6-month, randomized, 
double-blind, parallel group
6-month, randomized, double-blind, 
double dummy, parallel group
12-month, randomized, open-label, 
parallel group
Countries/sites 17/184 16/235 16/246
Treatment comparison fP/salm 500/50 µg x1 
inhalation bid + terb as 
needed
Bud/form 160/4.5 µg x2 
inhalation bid + Bud/form 
as needed
fP/salm 125/25 µg x 2 inhalation bid + terb 
as needed
Bud/form 320/9 µg x1 inhalation bid + terb 
as neededd
Bud/form 160/4.5 µg x1 inhalation 
bid + Bud/form as needed
fP/salm 250/50 µg x1 inhalation bid 
(dose could be changed to 100/50 µg 
x1 inhalation bid or 500/50 µg x1 
inhalation bid) + salb as needed
Bud/form 160/4.5 µg x2 inhalations bid 
(dose could be changed to 160/4.5 µg 
x1 inhalations bid) + Bud/form as 
needed




mean age (years) 39 38 45
mean baseline fEV1 % 
predicted (%)
71 73 73
Primary endpoint time to first severe 
exacerbation
time to first severe exacerbation time to first severe exacerbation





dData from this study arm not included in economic analysis.
high-income countries in Europe (19–22), Canada (23) and 
Australia (21). To date, cost comparison data have been 
reported rarely for middle- or lower middle-income coun-
tries. A cost comparison in Thailand based on one head-to-
head study reported slightly lower drug costs with the FP/
salm compared with the MART regimen and similar overall 
direct costs (24).
The aim of this analysis was to compare the direct costs 
of FP/salm and MART in three Southeast Asian countries 
(Indonesia, Thailand and Vietnam) based on published data 
from three RCTs where the two treatments have been com-
pared head-to-head (25–27). These countries were selected 
since the cost data for medications and health resources are 
publicly available. They may also be considered to be a rep-
resentative sample of Southeast Asia in terms of population 
diversity, development and access to healthcare and medicines.
Methods
Clinical trials
A literature review was performed using Pubmed to identify 
RCTs comparing regular twice-daily FP/salm plus as needed 
SABA (hereafter referred to as FP/salm) versus budesonide/
formoterol MART (hereafter referred to as MART) in adults 
and adolescents aged ≥12 years with asthma. Pubmed search 
terms included, “salmeterol/fluticasone”; “sal/flu”; “mainte-
nance and reliever therapy”; “MART”; “randomized con-
trolled trials”; “RCTs”. Studies that recorded resource 
utilization data prospectively were identified, namely the 
AHEAD (NCT00242775 (25), COMPASS study (AstraZeneca 
study code SD-039-0735) (26) and COSMOS (AstraZeneca 
study code SD-039-0691) (27) trials. A summary of the 
study designs for each trial is shown in Table 1. AHEAD 
and COMPASS were double-blind, 6-month studies and 
COSMOS was an open-label 12-month study. The patient 
populations were similar across studies (mean baseline per-
cent of predicted FEV1 71% to 73%). For this analysis, only 
data from the relevant FP/salm and MART treatment arms 
have been included.
Resource utilization data
During all studies, the following resource use data were col-
lected via patient notebooks or event logs: hospitalizations 
(intensive care and general ward), emergency room (ER) 
visits, and other healthcare visits including general practitioner 
(GP), specialist, physiotherapist and nurse (25–27). Scheduled 
study visits were excluded from the cost analyses. Medication 
use was either recorded in daily diaries and checked by the 
investigators at study visits (AHEAD and COMPASS) (25,26), 
or retrospective patient-reported medication use during the 
preceding 2 weeks recorded at clinic visits (COSMOS) (27). 
The dosing regimen for FP/salm and MART differed for the 
three studies in terms of medication inhalations per day as 
shown in Table 1. In addition, dose titrations were permitted 
in COSMOS but not in AHEAD or COMPASS.
Data concerning resource use were pooled across partic-
ipating countries for each study and, for comparative pur-
poses, data from the 6-month studies were extrapolated to 
12 months - as reported previously (22).
Economic analysis
Unit costs of branded medications and healthcare services in 
individual countries were obtained from publicly available 
sources (24,28–39) (Table 2). Where available, costs were 
based on the licensed dose (i.e. the dose approved in each 
country) and 60-dose (dry powder inhaler) or 120-dose 
(metered dose inhaler) packs, and were expressed as per dose/
puff costs. In Thailand, terbutaline cost was not available so 
SABA costs were based on cost of salbutamol. In Vietnam, 
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FP/salm 100/50 (i.e. dry powder device) cost was not avail-
able, and per unit cost was assumed to be twice that of the 
FP/salm 125/25 (i.e. metered dose inhaler) unit cost, since 
these are clinically equivalent. Where the cost of health care 
visits for ‘other health care personnel’ (physiotherapist, occu-
pational therapist or similar professional) was unavailable in 
the specific country, this was priced as the average cost of a 
GP visit and a visit to a physiotherapist.
Unit costs in local currency were converted to British 
pound sterling (GBP) using the 2019 average exchange rate 
(28). An expert in each country provided external validity of 
individual costings. Total direct costs (including medication 
and non-medication costs) per patient per year were calcu-
lated for each type of healthcare resource by multiplying the 
frequency of use over one year by unit costs for each country.
Several univariate sensitivity analyses were performed to 
test the robustness of the results in this analysis. The first 
sensitivity analysis, examined the impact on results of chang-
ing the unit cost of hospitalizations. In the main analyses, 
the differentiated unit cost at an intensive care unit and 
general ward was used. In the first sensitivity analysis, the 
average cost of ICU and general ward was used for hospi-
talization costs. In the second sensitivity analysis, the unit 
cost for a visit to a specialist was set equal to the unit cost 
for a GP visit. This was done to reflect clinical practice, 
where patients most often visit their GP with respect to 
their asthma. Finally, in the last two analyses, the unit costs 
for hospitalizations, health care visits and home visits were 
increased or decreased by 10%.
A sensitivity analysis was also performed by varying the 
health care unit costs by 10% or 20% to give estimated 
boundaries for the total costs.
Results
Efficacy
In the three comparator studies between FP/salm and 
MART selected because they could provide health economic 
data for this analysis, the primary endpoint, time to first 
severe exacerbation, was significantly prolonged in patients 
using MART compared with FP/salm in the COSMOS and 




Cost (rupiah) Cost (GBP) Cost (baht) Cost (GBP) Cost (dong) Cost (GBP)
hospitalization, per 
day
 ICu 17,363,900a 961.56 5,070b 127.93 2,100,000c 71.38
 General ward 8,628,000a 477.79 1,953b 49.28 1,156,230c 39.30
healthcare visit, per 
visit
 Emergency room 1,198,100a 66.35 796.36d 20.09 1,267,750e 43.09
 specialist 200,000f 11.08 306g 7.72 313,777h 10.66
 General care 
physician
80,000f 4.43 101g 2.55 355,321h 12.08
 other 80,000f 4.43 118g 2.98 1,451,475h 49.33
home visit, per visit
 General care 
physician
80,000f 4.43 359.3g 9.07 1,451,475h 49.33




 Bud/form + Bud/
form (160/4.5 µg)
2,238i 0.12 7.42j 0.19 5,001k 0.17
 Bud/form (320/9 µg) n/a n/a 10.52j 0.27 n/a n/a
 fP/salm (125/25 µg) 1,155l 0.07 2.50j 0.06 1,972.98k 0.07
 fP/salm (100/50 µg) 1,817i 0.10 6.42j 0.16 3,945.96l 0.07
 fP/salm (250/50 µg) 2,042i 0.11 7.79j 0.20 4,524.80k 0.15
 fP/salm (500/50 µg) 2,233i 0.12 9.95j 0.25 5,865.40k 0.20
 salbutamol 157i 0.01 0.23j 0.01 470.38k 0.02
 terbutaline (0.4 mg) 622i 0.03 0.23j 0.01 470.38k 0.02
Notes. Cost of fP/salm 100/50 (i.e. dry powder device) was not available, and per unit cost was assumed 
twice that of the fP/salm 125/25 (i.e. metered dose inhaler), since these are clinically equivalent. Bud/
form: budesonide/formoterol; fP/salm: fluticasone propionate/salmeterol; ICu: intensive care unit.
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COMPASS studies (26,27) with no significant difference 
between treatments shown in the AHEAD study (25). The 
yearly exacerbation rate ranged from 0.24 to 0.25 for the 
MART and 0.31–0.38 for FP/salm treatment. Both treat-
ments resulted in similar improvements in asthma control 
scores, asthma symptoms and lung function.
Resource utilization data
Overall, healthcare resource use was relatively low in all 
three studies (Table 3). The most common healthcare use 
in all studies were visits to GPs and specialists and there 
were no notable differences between treatments in the fre-
quency of these visits.
Economic analysis
Average total direct costs per patient per year were consis-
tently lower for those who used FP/salm compared with 
MART, with one exception (Indonesia/COMPASS study) 
(Table 4; Figure 1). Total average (minimum-maximum) 
direct costs (in GBP/patient/year) across the three studies 
Table 3. average resource use per patient per year by treatment option in each study.
AHEADa,b COMPASSb,c COSMOSb,d
fP/salm mart fP/salm mart fP/salm mart
hospitalization
 ICu 0 0.01 0.012 0.048 0.005 0.009
 General ward 0.05 0.06 0.296 0.074 0.09 0.05
healthcare visit
 ED 0.104 0.094 0.178 0.134 0.06 0.04
 specialist 0.240 0.152 0.408 0.314 0.24 0.17
 GP 0.192 0.168 0.270 0.282 0.37 0.32
 other 0.056 0.028 0.096 0.074 0.10 0.05
home visit
 GP 0.016 0.010 0.016 0.006 0.04 0.03
 other 0.006 0.002 0.044 0.006 0.01 0
medication (per patient 
per day)
 Bud/form + Bud/form 
(160/4.5 µg)
– 4.879 – 3.250 – 3.940
 Bud/form (320/9 µg) – – – – – –
 fP/salm (125/25 µg) – – 4.304 – – –
 fP/salm (100/50 µg) – – – – 0.233 –
 fP/salm (250/50 µg) – – – – 1.214 –
 fP/salm (500/50 µg) 1.978 – – – 0.490 –
 salbutamol – – – 0.907 –
 terbutaline (0.4 mg) 0.995 – 1.036 – – –
Notes. Data for ahEaD and ComPass studies extrapolated to 1 year. Bud/form: budesonide/
formoterol; ED: emergency department; fP/salm: fluticasone propionate/salmeterol; GP: general 
practitioner; ICu: intensive care unit.
areference (25).
bresource use data from reference (24).
creference (26).
dreference (27).






total direct costs 
(GBP)
ahEaDa ID – fP/salm 102 35 137
ID – mart 220 47 267
th – fP/salm 183 7 190
th – mart 332 8 340
Vt – fP/salm 149 15 164
Vt – mart 302 13 315
ComPassb ID – fP/salm 113 171 284
ID – mart 147 96 243
th – fP/salm 101 24 125
th – mart 221 16 237
Vt – fP/salm 111 35 146
Vt – mart 201 23 224
Cosmosc ID – fP/salm 83 57 140
ID – mart 178 39 217
th – fP/salm 147 10 157
th – mart 268 7 275
Vt – fP/salm 120 21 141
Vt – mart 244 14 258
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were £187 (£137–£284), £158 (£125–£190), and £151 (£141–
£164) for those who used FP/salm, and £242 (£217–£267), 
£284 (£237–£340) and £266 (£224–£315) for MART in 
Indonesia, Thailand and Vietnam, respectively. On average, 
total costs per-patient per-year were 22.8%, 44.6% and 43.0% 
lower with FP/salm than MART for Indonesia, Thailand 
and Vietnam, respectively (Figure 2).
These differences were largely driven by the medication 
costs of each treatment regimen as in all countries the cost 
of MART treatment was higher than FP/salm treatment, 
whereas healthcare costs were generally higher with FP/salm 
versus MART treatment (Table 4). The exceptions to this 
were that healthcare costs in Indonesia and Thailand in the 
AHEAD study were slightly lower with FP/salm treatment 
versus MART.
The robustness of the presented analyses was tested by 
varying several parameters which could have impacted the 
unit costs of either hospitalizations or other healthcare visits. 
In each of the four sensitivity analyses conducted, the results 
of the analysis and conclusions remained unchanged.
Discussion
The results of this analysis showed that, overall, regular 
twice-daily FP/salm was associated with lower direct 
healthcare costs compared with MART, despite the slightly 
higher exacerbation rates, and these findings were largely 
consistent across the three studies and the three countries 
evaluated. In general, healthcare resource use was low in 
all three studies, in keeping with the relatively low 
reported rates of severe exacerbations and accounting for 
the observation that differences in total direct costs were 
driven by the higher costs of MART than FP/salm treat-
ment regimens.
Asthma-related costs impose a high burden on individual 
countries and costs differ between countries depending on 
several factors such as a country’s gross domestic product 
(GDP), type of healthcare system and public health resources 
(40). Studies reporting the economic costs of the FP/salm 
and MART regimens in high-income countries, have shown 
less marked differences between treatments in terms of total 
direct costs, and no trend on one direction across studies, 
probably related to their different healthcare systems and 
drug pricing criteria (19–23). A previous analysis of cost 
data in Thailand based on the COMPASS study reported 
slightly lower drug costs with the FP/salm versus MART 
regimen and similar overall direct costs (24). Payers in 
Southeast Asian countries define cost thresholds or eco-
nomic evaluation criteria relevant and specific to their 
healthcare system. In Indonesia, there is a single-payer, uni-
versal healthcare program called the National Health 
Insurance System (Jaminan Kesehatan Nasional – JKN) 
which provides cover for the majority of the population 
(41). In Thailand, universal healthcare is provided and reim-
bursed through three government schemes, and direct med-
ical costs and specifically drug costs are an important 
consideration when prescribing medication. Vietnam has a 
Figure 1. average total direct costs by treatment option in each 
study in (a) Indonesia, (b) thailand and (c) Vietnam.
Figure 2. average total direct costs by treatment option across 
all studies in Indonesia, thailand and Vietnam.
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tiered health system and per patient visit cost thresholds 
are applicable within all medical care institutions other than 
the largest, regional central hospitals. In order to fall within 
thresholds, physicians may reduce the time between patient 
visits to reduce medication costs.
Our goal in this analysis was to reflect clinical practice, 
drug usage and costing; therefore, the real-world price of 
treatments in each country were used in our calculations. 
The difference in drug acquisition cost was a key driver 
of the overall cost presented per regime in this study, and 
these data will provide important information to decision 
makers. Both physicians and payers have to weigh up the 
overall evidence based on clinical data (efficacy, safety) 
and costs. In the three countries evaluated in this analysis, 
local asthma guidelines recommend both regular ICS/LABA 
and MART as preferred treatment options for moderate/
severe asthma (42–44). In a recent survey of physicians in 
Asia, in addition to treatment guidelines and physician’s 
personal experience, patient affordability of treatment was 
identified as an important factor influencing the choice of 
treatment by physicians for patients with asthma and 
co-existent rhinitis (45). Although hospitalizations due to 
asthma pose a significant cost, medications are the major 
contributor to overall costs of maintenance-treatment 
asthma management (1,46), since there are many patients 
with asthma but only a relative minority experience hos-
pital admission (4,46). The data from our analysis showed 
that costs of medication was the most important driver of 
direct costs.
In the three studies that could be included in this anal-
ysis, differences in yearly exacerbation rates were very small 
but were significantly in favor of the MART strategy (25–
27). Even in these studies where MART was associated with 
lower exacerbation rates, direct healthcare costs were lower 
with FP/salm. Across a range of clinical studies, superior 
benefit of MART is not consistently demonstrated (15,16,47–
51). The cost advantage of FP/salm reported in this analysis, 
may therefore also apply more widely, dependent on local 
medication and treatment costs. In future research, inclusion 
of a budget impact analysis of different treatment regimens 
for asthma with country specific epidemiological data, or 
factoring asthma control into healthcare cost computations 
would be of added interest.
A main limitation of this analysis is that we could not 
include indirect costs associated with asthma, such as 
absenteeism, because of difficulties in obtaining consistent 
estimates of unit costs in the countries included in this 
analysis; instead we focused on direct costs associated with 
healthcare resource use and medication costs. Even though 
the countries included in this analysis were similar in terms 
of populations, development and access to healthcare, the 
costing data with these three countries in Southeast Asia 
may not be representative more extensively. However, our 
analysis prepares the way for future such research. While 
the majority of unit costs data were obtained from publicly 
available, verifiable resources, we were required to make a 
limited number of assumptions about individual unit cost-
ings where a particular drug or drug formulation was not 
available in a particular country. However, these were ratio-
nal assumptions based on clinically equivalent alternatives, 
and were validated with a local expert in the relevant coun-
try, as is a standard practice for these types of healthcare 
cost studies. A further criticism may be the lack of inclu-
sion of recent clinical trials; all of those included here were 
undertaken over a decade ago, although the approach in 
clinical practice and treatment guideline recommendations 
for moderate asthma are largely the same (1,51). Another 
limitation is that resource use data were based on clinical 
trials only, using data collected in notebooks or event logs, 
although this is commonly used in cost-effectiveness anal-
yses and reported to have high internal validity (22). The 
same resource use data have been used and reported in 
several other cost analyses publications based on these stud-
ies (19–24). With respect to external validity, the three 
countries included in this analysis participated in the 
AHEAD study, Thailand and Vietnam participated in the 
COMPASS study, and Vietnam participated in the COSMOS 
study. The external validity of these data was also provided 
by advice taken from experts in each country. While the 
use of clinical trials data was helpful at standardizing data 
collection across multiple geographies, further data collec-
tion should be done to measure the real-world impact of 
different treatment approaches in asthma.
Conclusion
This study showed that, overall, treatment with regular 
twice-daily FP/salm is associated with lower direct healthcare 
costs than budesonide/formoterol MART. This difference 
was consistent across the three countries evaluated. These 
data provide important information for both physicians and 
payers with respect to treatment decisions for patients with 
moderate asthma in Indonesia, Thailand and Vietnam.
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